Performance in Delivering Clinical Research - Quarter 2 (2019/2020)											
Note: Chelsea and Westminster Hospital NHS Foundation Trust formally acquired West Middlesex University Hospital NHS Foundation Trust on 01/09/2015, and the submission for the former West Middlesex University Hospital NHS Trust has been subsumed into this submission											
All hosted, commercial clinical trials closed to recruitment between 1st October 2018 - 30th September 2019											
	Name of Trial									Reason For Closure Of Trial	Comments
		Patients Agreed?									
					Agreed?			Recruitment			
			One Number)			patients	Target Date				
243519		Range Agreed	5	8	Not Available /			24/10/2018	5	Recruitment Finished	None
	(Tecentriq) to investigate long-term safety and efficacy in				Not Agreed						
	previously-treated patients with locally advanced or										
	metastatic non-small cell lung cancer (TAIL)										
1											
	Integrated Research Application System 243519	Integrated Name of Trial Research Application System	Integrated Research Application System 243519 A Phase III/IV, single arm, mutlicentre study of atezolizumab (Tecentria) to investigate long-term safety and efficacy in previously-treated patients with locally advanced or	Integrated Research Application System 243519 A Phase III/IV, single arm, mutilicentre study of atezolizumab (Tecentriq) to investigate long-term safety and efficacy in previously-treated patients with locally advanced or	Integrated Research Application System 243519 A Phase III/IV, single arm, mutilicentre study of atezolizumab (Tecentriq) to investigate long-term safety and efficacy in previously-treated patients with locally advanced or	Integrated Research Application System 243519 A Phase III/IV, single arm, mutilicentre study of atezolizumab (Tecentriq) to investigate long-term safety and efficacy in previously-treated patients with locally advanced or	Integrated Research Application System 243519 A Phase III/IV, single arm, mutlicentre study of atezolizumab (Tecentric) to investigate long-term safety and efficacy in previously-treated patients with locally advanced or	Integrated Research Application System 243519 A Phase III/IV, single arm, mutlicentre study of atezolizumab (Tecentriq) to investigate long-term safety and efficacy in previously-treated patients with locally advanced or	Integrated Research Application System 243519 A Phase III/IV, single arm, mutilicentre study of atezolizumab (Tecentriq) to investigate long-term safety and efficacy in previously-treated patients with locally advanced or	Integrated Research Application System 243519 A Phase IIII/IV, single arm, mutlicentre study of atezolizumab (Tecentriq) to investigate long-term safety and efficacy in previously-treated patients with locally advanced or	Integrated Research Application System 243519 A Phase III/IV, single arm, mutlicentre study of a fezolizumab for previously-treated patients with locally advanced or experiment sets of the first of the former was third locally advanced or experiment between 1st October 2018 - 30th September 2019 Target Number Of Patients Agreed (Enter Same In Both If Only One Number) Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number) Same In Both If Only One Number) Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number) Same In Both If Only One Number) Not Available / Not Agreed Not Available / Not Agreed Target Date Total Number Of Patients Recruited Trial Closed To Patients Recruited Trial Closed To Patients Recruited Target Date 24/10/2018 5 Recruitment Finished